title: Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram.
abstract: OBJECTIVE
  Three recent observational studies reported that the risk of fatal overdose is greater with venlafaxine than SSRI use. It is not clear whether patient factors could account for this finding. We evaluated whether risk factors for suicide are more prevalent among patients prescribed venlafaxine than patients prescribed fluoxetine or citalopram.
  
  
  METHODS
  Using data from the UK General Practice Research Database (GPRD), we identified patients who were first prescribed any of the three drugs between January 1995 and April 2002. We ascertained risk factors for suicide documented in the 1 year before that first prescription. Separate analyses compared venlafaxine (N = 27 096) and fluoxetine (N = 134 996) cohorts, and venlafaxine and citalopram (N = 52 035) cohorts.
  
  
  RESULTS
  Previous suicidal behaviors were documented for 1.0% of the venlafaxine cohort compared to 0.4% of the fluoxetine cohort (OR 2.8, 95%CI: 2.4, 3.2) and 0.4% citalopram cohorts (OR 2.4, 95%CI: 2.0, 2.9). 72.5% of venlafaxine patients had been prescribed at least one other antidepressant compared to 27.6% of fluoxetine (OR 6.9, 95%CI: 6.7, 7.1) and 39.5% of citalopram (OR 4.0, 95%CI: 3.9, 4.2) patients. Venlafaxine patients were also four to six times as likely to have been previously hospitalized for depression.
  
  
  CONCLUSIONS
  In the UK, venlafaxine has been selectively prescribed to a patient population with a higher burden of suicide risk factors than patients prescribed fluoxetine and citalopram. Unless baseline population differences are accounted for, observational studies that compare the risk of suicide in patients receiving these agents may produce biased results.
authors.affiliation: Global Safety Surveillance and Epidemiology, Wyeth Research, Collegeville, PA 19426-3930, USA. minesd@wyeth.com
authors.forename: Daniel
authors.initials: D
authors.lastname: Mines
authors.forename: Deanna
authors.initials: D
authors.lastname: Hill
authors.forename: Holly
authors.initials: H
authors.lastname: Yu
authors.forename: Laura
authors.initials: L
authors.lastname: Novelli
mesh_terms: D000293:Adolescent; D000328:Adult; D000341:Affective Disorders, Psychotic / Q000188:drug therapy; D000368:Aged; D000369:Aged, 80 and over; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D015283:Citalopram / Q000009:adverse effects / Q000627:therapeutic use; D015331:Cohort Studies; D003511:Cyclohexanols / Q000009:adverse effects / Q000627:therapeutic use; D016208:Databases, Factual / Q000706:statistics & numerical data; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012307:Risk Factors; D012737:Sex Factors; D013406:Suicide, Attempted / Q000706:statistics & numerical data* / Q000639:trends; D013997:Time Factors; D006113:United Kingdom / Q000453:epidemiology; D000069470:Venlafaxine Hydrochloride
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D005473:Fluoxetine; D015283:Citalopram; D000069470:Venlafaxine Hydrochloride